Lakefront Biotherapeutics (LKFT) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lakefront Biotherapeutics (LKFT) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 14.1% versus a loss of 41.3%. Mineralys Therapeutics is the larger company by market cap ($1.96 billion vs $1.94 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | MLYS |
|---|---|---|
| Share price | $29.55 | $22.18 |
| Market cap | $1.94B | $1.96B |
| 1-day change | -1.50% | +0.41% |
| YTD return | -8.26% | -39.13% |
| 1-year return | -14.11% | -41.34% |
| 5-year return | -43.95% | — |
| P/E ratio (TTM) | 2.81 | — |
| EPS (TTM) | $10.52 | $-4.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.24 | $47.65 |
| 52-week low | $25.68 | $21.46 |
| Distance from 52-week high | -18.46% | -53.45% |
| Analyst consensus | hold | none |
| Avg. price target upside | +2.13% | +118.67% |
| Average volume | 267.27K | 1.03M |
| Shares outstanding | 65.48M | 88.41M |
| Employees | 196 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LKFT has outperformed MLYS by 27.2 percentage points over the past year.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
LKFT vs MLYS FAQ
Which is bigger, Lakefront Biotherapeutics or Mineralys Therapeutics?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.96B compared with $1.94B for Lakefront Biotherapeutics (LKFT).
Which stock has performed better over the past year, LKFT or MLYS?
LKFT returned -14.11% over the past 12 months, compared with -41.34% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and Mineralys Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.